KENGREAL 50 mg/1

Kengreal 50 mg/1 is a lyophilized powder for solution, used for intravenous administration. This medication is indicated for specific cardiovascular procedures to reduce the risk of periprocedural ischemic complications.

Kengreal is primarily used in patients undergoing percutaneous coronary intervention (PCI) to reduce the risk of periprocedural ischemic complications. It is often employed in procedures where antiplatelet therapy is required to prevent blood clots. The medication is designed to provide rapid and reversible antiplatelet effects, making it suitable for use during cardiovascular interventions.

Common effects of Kengreal may include bleeding at the injection site or other areas of the body. Some patients might experience dizziness or nausea. These effects are generally mild and transient, but any persistent or severe symptoms should be reported to a healthcare provider.

Kengreal should be handled with care, ensuring proper storage and preparation. It is important to follow the instructions for reconstitution and administration to maintain its efficacy. Patients with a history of bleeding disorders or those taking other anticoagulants should use this medication under medical supervision.

Kengreal may interact with other anticoagulants or antiplatelet drugs, increasing the risk of bleeding. It is important to inform healthcare providers about all medications being taken, including over-the-counter drugs and supplements, to avoid potential interactions.